Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7453MR)

This product GTTS-WQ7453MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7453MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2810MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ15537MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ8905MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ2365MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ9548MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ13993MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ15792MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ766MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AB0024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW